By contrast, after tumours with EWSR1 rearrangements are excluded (see below), only ~50% of clinically malignant Sertoli cell tumours NOS show evidence of Wnt pathway activation by gain‐of‐function CTNNB1 mutations. Here, CTNNB1 is linked to neoplasm.